Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Association between MuSK antibody concentrations and the Myasthenia Gravis Composite Score in three patients: A marker of relapse?

Triplett JD, Hardy TA, Riminton DS, Chu SKY, Reddel SW.

Muscle Nerve. 2019 Jun 8. doi: 10.1002/mus.26609. [Epub ahead of print]

PMID:
31177576
2.

Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.

Reddel SW.

Mult Scler. 2019 Mar 18:1352458519835440. doi: 10.1177/1352458519835440. [Epub ahead of print] No abstract available.

PMID:
30882272
3.

Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes).

Triplett JD, Buzzard KA, Lubomski M, Riminton DS, Barnett MH, Welgampola MS, Halmagyi GM, Nguyen M, Landau K, Lee AG, Plant GT, Fraser CL, Reddel SW, Hardy TA.

J Neurol Neurosurg Psychiatry. 2019 Mar 9. pii: jnnp-2018-319002. doi: 10.1136/jnnp-2018-319002. [Epub ahead of print] Review.

PMID:
30852493
4.

Pachymeningitis Demonstrated on Gallium SPECT/CT Scan.

Wong VC, Yung G, Russo R, Reddel SW, Mansberg R.

Clin Nucl Med. 2019 Apr;44(4):305-309. doi: 10.1097/RLU.0000000000002484.

PMID:
30762818
5.

Warts and all: Fingolimod and unusual HPV-associated lesions.

Triplett J, Kermode AG, Corbett A, Reddel SW.

Mult Scler. 2018 Nov 14:1352458518807088. doi: 10.1177/1352458518807088. [Epub ahead of print]

PMID:
30427266
6.

Forearm-predominant parainfectious myositis.

Triplett J, Rigney L, Hardy TA, Barnett Y, Hayes MW, Barnett M, Reddel SW.

Muscle Nerve. 2019 Feb;59(2):E7-E10. doi: 10.1002/mus.26367. Epub 2018 Dec 21. No abstract available.

PMID:
30376690
7.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium .

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

8.

Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.

Reddel SW, Barnett MH, Riminton S, Dugal T, Buzzard K, Wang CT, Fitzgerald F, Beadnall HN, Erickson D, Gahan D, Wang D, Ackland T, Thompson R.

Mult Scler. 2019 Jul;25(8):1124-1131. doi: 10.1177/1352458518783673. Epub 2018 Jun 18.

PMID:
29911471
9.

Cannabinoid-induced increase of quantal size and enhanced neuromuscular transmission.

Morsch M, Protti DA, Cheng D, Braet F, Chung RS, Reddel SW, Phillips WD.

Sci Rep. 2018 Mar 16;8(1):4685. doi: 10.1038/s41598-018-22888-4.

10.

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.

Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group.

J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. doi: 10.1136/jnnp-2017-316880. Epub 2017 Nov 15.

11.

The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.

Ghazanfari N, Trajanovska S, Morsch M, Liang SX, Reddel SW, Phillips WD.

Ann N Y Acad Sci. 2018 Jan;1412(1):54-61. doi: 10.1111/nyas.13513. Epub 2017 Nov 10. Review.

PMID:
29125188
12.

A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers.

Mori AM, Agarwal S, Lee MWM, Rafferty M, Hardy TA, Coles A, Reddel SW, Riminton DS.

J Neuroimmunol. 2017 Nov 15;312:4-7. doi: 10.1016/j.jneuroim.2017.08.009. Epub 2017 Aug 24.

PMID:
28886954
13.

Postnatal Development of Spasticity Following Transgene Insertion in the Mouse βIV Spectrin Gene (SPTBN4).

Kichkin E, Visvanathan A, Lovicu FJ, Shu DY, Das SJ, Reddel SW, McCann EP, Zhang KY, Williams KL, Blair IP, Phillips WD.

J Neuromuscul Dis. 2017;4(2):159-164. doi: 10.3233/JND-160197.

PMID:
28582869
14.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

PMID:
28550069
15.

Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.

Barton J, Hardy TA, Riminton S, Reddel SW, Barnett Y, Coles A, Barnett MH.

Neurology. 2017 Mar 7;88(10):1004-1006. doi: 10.1212/WNL.0000000000003694. Epub 2017 Feb 8. No abstract available.

PMID:
28179462
16.

Variants in the Oxidoreductase PYROXD1 Cause Early-Onset Myopathy with Internalized Nuclei and Myofibrillar Disorganization.

O'Grady GL, Best HA, Sztal TE, Schartner V, Sanjuan-Vazquez M, Donkervoort S, Abath Neto O, Sutton RB, Ilkovski B, Romero NB, Stojkovic T, Dastgir J, Waddell LB, Boland A, Hu Y, Williams C, Ruparelia AA, Maisonobe T, Peduto AJ, Reddel SW, Lek M, Tukiainen T, Cummings BB, Joshi H, Nectoux J, Brammah S, Deleuze JF, Ing VO, Ramm G, Ardicli D, Nowak KJ, Talim B, Topaloglu H, Laing NG, North KN, MacArthur DG, Friant S, Clarke NF, Bryson-Richardson RJ, Bönnemann CG, Laporte J, Cooper ST.

Am J Hum Genet. 2016 Nov 3;99(5):1086-1105. doi: 10.1016/j.ajhg.2016.09.005. Epub 2016 Oct 13.

17.

Extensive Postradiation Ocular and Diffuse Cranial Neuromyotonia Mimicking Myasthenia Gravis.

Hardy TA, Lee AW, Yiannikas C, Chen CS, Reddel SW.

Neurologist. 2016 Sep;21(5):79-82. doi: 10.1097/NRL.0000000000000088.

PMID:
27564076
18.

Atypical inflammatory demyelinating syndromes of the CNS.

Hardy TA, Reddel SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG.

Lancet Neurol. 2016 Aug;15(9):967-981. doi: 10.1016/S1474-4422(16)30043-6. Review.

PMID:
27478954
19.

Whole Genome Sequencing Identifies a 78 kb Insertion from Chromosome 8 as the Cause of Charcot-Marie-Tooth Neuropathy CMTX3.

Brewer MH, Chaudhry R, Qi J, Kidambi A, Drew AP, Menezes MP, Ryan MM, Farrar MA, Mowat D, Subramanian GM, Young HK, Zuchner S, Reddel SW, Nicholson GA, Kennerson ML.

PLoS Genet. 2016 Jul 20;12(7):e1006177. doi: 10.1371/journal.pgen.1006177. eCollection 2016 Jul.

20.

Late presentations of congenital myasthenic syndromes: How many do we miss?

Garg N, Yiannikas C, Hardy TA, Belaya K, Cheung J, Beeson D, Reddel SW.

Muscle Nerve. 2016 Oct;54(4):721-7. doi: 10.1002/mus.25085. Epub 2016 Jul 9.

PMID:
26910802
21.

Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis.

Ghazanfari N, Linsao EL, Trajanovska S, Morsch M, Gregorevic P, Liang SX, Reddel SW, Phillips WD.

Physiol Rep. 2015 Dec;3(12). pii: e12658. doi: 10.14814/phy2.12658. Epub 2015 Dec 22.

22.

MORC2 mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs.

Albulym OM, Kennerson ML, Harms MB, Drew AP, Siddell AH, Auer-Grumbach M, Pestronk A, Connolly A, Baloh RH, Zuchner S, Reddel SW, Nicholson GA.

Ann Neurol. 2016 Mar;79(3):419-27. doi: 10.1002/ana.24575. Epub 2016 Jan 13.

23.

Hyperekplexia as the presenting symptom of Creutzfeldt-Jakob disease.

Ramanathan S, Fung VSC, Bielich A, Masters L, Russo RR, Buckland ME, Sarros S, Klug GMJA, Collins S, Reddel SW.

Neurol Clin Pract. 2015 Dec;5(6):498-501. doi: 10.1212/CPJ.0000000000000150. No abstract available.

24.

Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned.

Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, Needham M, Liang C, Waddell LB, Nicholson G, O'Grady G, Kaur S, Ong R, Davis M, Sue CM, Laing NG, North KN, MacArthur DG, Clarke NF.

JAMA Neurol. 2015 Dec;72(12):1424-32. doi: 10.1001/jamaneurol.2015.2274.

PMID:
26436962
25.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
26.

Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.

Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, Vucic S, Gorman MP, Benson LA, Alper G, Riney CJ, Barnett M, Parratt JD, Hardy TA, Leventer RJ, Merheb V, Nosadini M, Fung VS, Brilot F, Dale RC.

Mult Scler. 2016 Apr;22(4):470-82. doi: 10.1177/1352458515593406. Epub 2015 Jul 10.

PMID:
26163068
27.

Tablet-based screening improves continence management in multiple sclerosis.

Beadnall HN, Kuppanda KE, O'Connell A, Hardy TA, Reddel SW, Barnett MH.

Ann Clin Transl Neurol. 2015 Jun;2(6):679-87. doi: 10.1002/acn3.205. Epub 2015 May 1.

28.

Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.

Ramanathan S, Langguth D, Hardy TA, Garg N, Bundell C, Rojana-Udomsart A, Dale RC, Robertson T, Mammen AL, Reddel SW.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 2;2(3):e96. doi: 10.1212/NXI.0000000000000096. eCollection 2015 Jun.

29.

The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases.

Garg N, Reddel SW, Miller DH, Chataway J, Riminton DS, Barnett Y, Masters L, Barnett MH, Hardy TA.

J Neurol Neurosurg Psychiatry. 2015 Dec;86(12):1374-82. doi: 10.1136/jnnp-2014-309649. Epub 2015 Apr 9. Review.

PMID:
25857658
30.

Distinguishing Susac's syndrome from multiple sclerosis.

Buzzard KA, Reddel SW, Yiannikas C, Sean Riminton D, Barnett MH, Hardy TA.

J Neurol. 2015 Jul;262(7):1613-21. doi: 10.1007/s00415-014-7628-9. Epub 2014 Dec 30. Review.

PMID:
25547511
31.

Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis.

Buzzard KA, Meyer NJ, Hardy TA, Riminton DS, Reddel SW.

Muscle Nerve. 2015 Aug;52(2):204-10. doi: 10.1002/mus.24536. Epub 2015 Jun 18.

PMID:
25487528
32.

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.

Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt PN, Merheb V, Kumaran RY, Pathmanandavel K, Sinmaz N, Ghadiri M, Yiannikas C, Vucic S, Stewart G, Bleasel AF, Booth D, Fung VS, Dale RC, Brilot F.

Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40. doi: 10.1212/NXI.0000000000000040. eCollection 2014 Dec.

33.

Brain histopathology in three cases of Susac's syndrome: implications for lesion pathogenesis and treatment.

Hardy TA, O'Brien B, Gerbis N, Barnett MH, Reddel SW, Brewer J, Herkes GK, Silberstein P, Garsia RJ, Watson JD, Gupta R, Parratt JD, Buckland ME.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):582-4. doi: 10.1136/jnnp-2014-308240. Epub 2014 Aug 28. No abstract available.

PMID:
25168394
34.

Clinical and scientific aspects of muscle-specific tyrosine kinase-related myasthenia gravis.

Reddel SW, Morsch M, Phillips WD.

Curr Opin Neurol. 2014 Oct;27(5):558-65. doi: 10.1097/WCO.0000000000000136. Review.

PMID:
25159928
35.

Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.

Tarr TB, Lacomis D, Reddel SW, Liang M, Valdomir G, Frasso M, Wipf P, Meriney SD.

J Physiol. 2014 Aug 15;592(16):3687-96. doi: 10.1113/jphysiol.2014.276493. Epub 2014 Jul 11.

36.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
37.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
38.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
39.

Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction.

Ghazanfari N, Morsch M, Reddel SW, Liang SX, Phillips WD.

J Physiol. 2014 Jul 1;592(13):2881-97. doi: 10.1113/jphysiol.2013.270207. Epub 2014 May 23.

40.

Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis.

Ghazanfari N, Morsch M, Tse N, Reddel SW, Phillips WD.

PLoS One. 2014 Feb 5;9(2):e87840. doi: 10.1371/journal.pone.0087840. eCollection 2014.

41.

Anncaliia algerae microsporidial myositis.

Watts MR, Chan RC, Cheong EY, Brammah S, Clezy KR, Tong C, Marriott D, Webb CE, Chacko B, Tobias V, Outhred AC, Field AS, Prowse MV, Bertouch JV, Stark D, Reddel SW.

Emerg Infect Dis. 2014 Feb;20(2):185-91. doi: 10.3201/eid2002.131126.

42.

Sequence of age-associated changes to the mouse neuromuscular junction and the protective effects of voluntary exercise.

Cheng A, Morsch M, Murata Y, Ghazanfari N, Reddel SW, Phillips WD.

PLoS One. 2013 Jul 3;8(7):e67970. doi: 10.1371/journal.pone.0067970. Print 2013.

43.

Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome.

Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D, Reddel SW, Garcia-Ocano A, Wipf P, Meriney SD.

J Neurosci. 2013 Jun 19;33(25):10559-67. doi: 10.1523/JNEUROSCI.4629-12.2013.

44.

Muscle-specific kinase antibodies: a novel cause of peripheral nerve hyperexcitability?

Simon NG, Reddel SW, Kiernan MC, Layzer R.

Muscle Nerve. 2013 Nov;48(5):819-23. doi: 10.1002/mus.23907. Epub 2013 Jun 26.

PMID:
23720161
45.

Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.

Morsch M, Reddel SW, Ghazanfari N, Toyka KV, Phillips WD.

J Physiol. 2013 May 15;591(10):2747-62. doi: 10.1113/jphysiol.2013.251827. Epub 2013 Feb 25.

46.

Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.

Morsch M, Reddel SW, Ghazanfari N, Toyka KV, Phillips WD.

Exp Neurol. 2012 Oct;237(2):286-95. doi: 10.1016/j.expneurol.2012.06.034. Epub 2012 Jul 10.

PMID:
22789393
47.

Expanding the clinical, radiological and neuropathological phenotype of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS).

Simon NG, Parratt JD, Barnett MH, Buckland ME, Gupta R, Hayes MW, Masters LT, Reddel SW.

J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):15-22. doi: 10.1136/jnnp-2011-301054. Epub 2011 Nov 5. Review.

PMID:
22056964
48.

Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab.

Chohan G, Barnett Y, Gibson J, Reddel SW, Barnett MH.

J Neurol Neurosurg Psychiatry. 2012 May;83(5):573-5. doi: 10.1136/jnnp-2011-300575. Epub 2011 Aug 19. No abstract available.

PMID:
21856693
49.

Distinctive genetic and clinical features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P₂ phosphatase FIG4.

Nicholson G, Lenk GM, Reddel SW, Grant AE, Towne CF, Ferguson CJ, Simpson E, Scheuerle A, Yasick M, Hoffman S, Blouin R, Brandt C, Coppola G, Biesecker LG, Batish SD, Meisler MH.

Brain. 2011 Jul;134(Pt 7):1959-71. doi: 10.1093/brain/awr148.

50.

Managing the risks of immunosuppression.

Riminton DS, Hartung HP, Reddel SW.

Curr Opin Neurol. 2011 Jun;24(3):217-23. doi: 10.1097/WCO.0b013e328346d47d. Review.

PMID:
21519254

Supplemental Content

Loading ...
Support Center